Drug Trial Radar · NCT07776691
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
802
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Mar 19, 2032
Study completion Oct 22, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Conditions
- Ovarian Cancer
- Ovarian Neoplasms
- Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
R-DXdBiological
R-DXd administered as an intravenously (IV) infusion
BevacizumabDrug
Administered as an intravenously IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 4 years
- Overall Survival (OS)Time frame: Up to approximately 5.5 years
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
MedStar Washington Hospital Center ( Site 0026)
Washington D.C., District of Columbia · Recruiting
Lahey Hospital & Medical Center ( Site 0031)
Burlington, Massachusetts · Recruiting
Zangmeister Cancer Center ( Site 0043)
Columbus, Ohio · Recruiting
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000)
Eugene, Oregon · Recruiting
Alliance Cancer Specialists (ACS) ( Site 8008)
Horsham, Pennsylvania · Recruiting
Texas Oncology - West Texas ( Site 8009)
Amarillo, Texas · Recruiting
Texas Oncology - Central/South Texas ( Site 8002)
Austin, Texas · Recruiting
Texas Oncology - DFW ( Site 8005)
Fort Worth, Texas · Recruiting
Texas Oncology - The Woodlands ( Site 8003)
The Woodlands, Texas · Recruiting
Texas Oncology - Northeast Texas ( Site 8004)
Tyler, Texas · Recruiting
Northwest Cancer Specialists (Compass Oncology) ( Site 8007)
Vancouver, Washington · Recruiting
Rambam Health Care Campus ( Site 1402)
Haifa, Israel · Recruiting
Sourasky Medical Center ( Site 1403)
Tel Aviv, Israel · Recruiting
Seoul National University Hospital ( Site 2301)
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System ( Site 2302)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 2303)
Seoul, South Korea · Recruiting
National Cheng Kung University Hospital ( Site 2601)
Tainan, Taiwan · Recruiting
Royal Lancaster Infirmary ( Site 2808)
Lancaster, Lancashire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.